Clinical and Health Care Use Characteristics of Patients Newly Starting Allopurinol, Febuxostat, and Colchicine for the Treatment of Gout

Gout is a common form of inflammatory arthritis with an increasing prevalence in developed countries. It is well known that many patients with gout have significant comorbidities and high health care utilization. We aimed to describe the clinical characteristics and health care utilization patterns in patients with gout who were newly prescribed allopurinol, febuxostat, or colchicine.

[1]  H. Sayles,et al.  Gout‐Related Health Care Utilization in US Emergency Departments, 2006 Through 2008 , 2013, Arthritis care & research.

[2]  Brian Sauer,et al.  The incident user design in comparative effectiveness research , 2013, Pharmacoepidemiology and drug safety.

[3]  K. Nair,et al.  Comparison of patient characteristics and gout-related health-care resource utilization and costs in patients with frequent versus infrequent gouty arthritis attacks. , 2012, Rheumatology.

[4]  R. Terkeltaub,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis , 2012, Arthritis care & research.

[5]  Charles King,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia , 2012, Arthritis care & research.

[6]  Hyon K. Choi,et al.  Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. , 2012, The American journal of medicine.

[7]  Hyon K. Choi,et al.  Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007-2008. , 2011, Arthritis and rheumatism.

[8]  M. Fuldeore,et al.  Chronic kidney disease in gout in a managed care setting , 2011, BMC nephrology.

[9]  Sebastian Schneeweiss,et al.  A combined comorbidity score predicted mortality in elderly patients better than existing scores. , 2011, Journal of clinical epidemiology.

[10]  R. Terkeltaub,et al.  Health care utilization in patients with gout. , 2011, Seminars in arthritis and rheumatism.

[11]  Y. Chen,et al.  Impact of allopurinol use on urate concentration and cardiovascular outcome , 2011, British journal of clinical pharmacology.

[12]  D. Rothenbacher,et al.  Contemporary epidemiology of gout in the UK general population , 2011, Arthritis research & therapy.

[13]  Hyon K. Choi,et al.  Epidemiology of gout in women: Fifty-two-year followup of a prospective cohort. , 2010, Arthritis and rheumatism.

[14]  D. Goldfarb,et al.  Gout and its comorbidities. , 2010, Bulletin of the NYU hospital for joint diseases.

[15]  H. Schumacher,et al.  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. , 2008, Arthritis and rheumatism.

[16]  V. Strand,et al.  Gout is associated with more comorbidities, poorer health-related quality of life and higher healthcare utilisation in US veterans , 2007, Annals of the rheumatic diseases.

[17]  L. Annemans,et al.  Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005 , 2007, Annals of the rheumatic diseases.

[18]  Chaoyang Li,et al.  Prevalence of the metabolic syndrome in patients with gout: the Third National Health and Nutrition Examination Survey. , 2007, Arthritis and rheumatism.

[19]  P Netter,et al.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[20]  H. Schumacher,et al.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.

[21]  J. T. Wulu,et al.  Regression analysis of count data , 2002 .

[22]  Pravin K. Trivedi,et al.  Regression Analysis of Count Data , 1998 .

[23]  S Shapiro,et al.  Confounding by indication? , 1997, Epidemiology.